EGFR+ UK Highlights the Role of Biomarkers in The House of Commons

On Wednesday, 24th January, EGFR+ UK attended a parliamentary event at The House of Commons. The meeting spotlighted the critical importance of genomics and biomarker testing in the diagnosis and treatment of cancer.

There were a number of inspiring speakers, including Angela, our chair, who delivered a fabulous patient voice speech that was very well received by both MPs, oncologists and healthcare professionals.

Everyone attending was determined to affect change, to improve care and outcomes for cancer patients. There was much discussion on the importance of precision medicine and personalised care and the role of all stakeholders in achieving the vision of improved standardised care and equity across the UK. The event was organised by AstraZeneca and The House of Commons, and we are so grateful to have had the opportunity to contribute to this vital conversation.